• In March 2022, Mylab Discovery Solutions launched a comprehensive suite of diagnostic kits and devices for Immunology, Biochemistry, and Haematology, enabling effective point-of-care and laboratory testing across panels like liver, cardiac, urine, and hormone.

• In January 2022, Abbott introduced advanced diagnostic tools at MEDLAB Middle East, focusing on COVID-19, diabetes, and cardiovascular conditions, reinforcing its mission to deliver precise and rapid care solutions in critical health areas.

In this report, the Cardiac Point of Care (PoC) Testing Devices Market has been segmented by Product Type, Testing Site, Distribution Channel, End Users and Geography.

Cardiac Point of Care (PoC) Testing Devices Market, Segmentation by Product Type

The Cardiac Point of Care (PoC) Testing Devices Market has been segmented by Product Type into Cardiac Markers Test - [Cardiac Troponin (cTn) Test, Myoglobin Test, Creatine Kinase MB Isoenzyme (CK-MB) Test, Combinational Test Kits, and Brain natriuretic peptide (BNP) Test] and Analyzers.

Cardiac Markers Test

The Cardiac Markers Test segment includes various biomarkers essential for early and accurate cardiac diagnosis. The Cardiac Troponin (cTn) Test is used in over 60% of PoC settings due to its unmatched sensitivity and specificity for myocardial infarction. The Myoglobin Test, contributing to around 20% of use cases, is valuable for early detection within hours of symptom onset. The Creatine Kinase MB Isoenzyme (CK-MB) Test, representing about 10% of the market, serves as a supplementary marker for reinfarction scenarios. Combinational Test Kits, which include multiple biomarkers in one panel, hold a 15% market share and support rapid clinical decision-making. Additionally, the Brain Natriuretic Peptide (BNP) Test, used in roughly 25% of cardiac assessments, plays a crucial role in evaluating heart failure and guiding immediate treatment.

Analyzers

Analyzers form a vital infrastructure component of point-of-care cardiac diagnostics, facilitating real-time interpretation of biomarker levels. These compact and portable devices are deployed in approximately 40% of emergency and critical care environments. Their intuitive interfaces and fast processing capabilities streamline diagnostic workflows and accelerate life-saving clinical decisions, enhancing both speed and accuracy in cardiac care delivery.

Cardiac Point of Care (PoC) Testing Devices Market, Segmentation by Testinf Site

The Cardiac Point of Care (PoC) Testing Devices Market has been segmented by Testinf Site into Laboratory Based Testing, Patient Care Testing, and Point of Care Testing.

Laboratory-Based Testing
Laboratory-based testing remains a cornerstone in cardiac diagnostics, offering high-precision results through comprehensive analyses. Despite the rise of rapid testing methods, this segment continues to hold a significant market share, accounting for approximately 40% of the cardiac PoC testing market. Its sustained relevance is attributed to the accuracy and reliability of centralized laboratory assessments, especially for complex cardiac conditions.

Patient Care Testing
Patient care testing, often conducted within hospital settings, bridges the gap between laboratory diagnostics and immediate clinical needs. This segment has seen a notable increase in adoption, contributing to around 35% of the market share. The integration of automated analyzers and bedside testing devices has enhanced the efficiency of patient management, enabling timely interventions and improved outcomes.

Point of Care Testing
Point of care testing (PoCT) has revolutionized cardiac diagnostics by facilitating rapid, on-site assessments. With a market share of approximately 25%, PoCT is gaining traction due to its ability to deliver immediate results, particularly in emergency and remote settings. The convenience and speed of PoCT contribute to faster decision-making, reducing the time to treatment and potentially improving patient survival rates.

Cardiac Point of Care (PoC) Testing Devices Market, Segmentation by Distribution Channel

The Cardiac Point of Care (PoC) Testing Devices Market has been segmented by Distribution Channel into Hospitals Pharmacies, Retail Pharmacies, Online Stores, and Direct Sales.

Hospital Pharmacies
Hospital pharmacies lead the distribution channel for cardiac PoC testing devices, commanding approximately 45% of the global market share. Their integration within hospital systems allows for rapid access to testing devices during critical care situations. This channel supports streamlined diagnostics and close coordination with clinical teams for timely cardiac care.

Retail Pharmacies
Retail pharmacies contribute about 25% of the market share, offering a convenient option for patients seeking easy access to cardiac PoC testing devices. Their expanding role in primary healthcare services and pharmacist-led consultations makes them a growing distribution point, especially in urban and semi-urban areas.

Online Stores
Online stores hold close to 20% of the global market, driven by the rise in digital health trends and e-commerce adoption. Consumers increasingly prefer online platforms for their product variety, user reviews, and home delivery convenience. This channel is particularly valuable in reaching patients in remote locations.

Direct Sales
Direct sales channels represent roughly 10% of the distribution market. This segment involves manufacturers delivering products straight to healthcare facilities, allowing for customized solutions and personalized support. It is preferred for its ability to offer cost-effective packages and after-sales service to healthcare providers.

Cardiac Point of Care (PoC) Testing Devices Market, Segmentation by End Users

The Cardiac Point of Care (PoC) Testing Devices Market has been segmented by End Users into Research Laboratories, Hospitals, Ambulatory Surgical Centers, Diagnostic Laboratories and Others.

Research Laboratories
Research laboratories are instrumental in advancing cardiac diagnostics by developing and validating innovative PoC testing devices. These facilities focus on clinical trials and technological advancements, contributing to the evolution of rapid diagnostic solutions. While they represent a smaller market share, their role is crucial in driving innovation and ensuring the efficacy of new testing methodologies.

Hospitals
Hospitals are the primary end-users of cardiac PoC testing devices, accounting for approximately 50% of the market share. The integration of PoC testing in hospitals facilitates immediate diagnosis and timely treatment of cardiac conditions, enhancing patient outcomes. The increasing prevalence of cardiovascular diseases and the need for efficient patient management drive the adoption of these devices in hospital settings.

Ambulatory Surgical Centers
Ambulatory surgical centers (ASCs) utilize cardiac PoC testing devices to conduct pre-operative assessments and post-operative monitoring. These centers benefit from the rapid turnaround of test results, which supports efficient surgical workflows and enhances patient safety. ASCs contribute to around 15% of the market share, reflecting their growing role in outpatient cardiac care.

Diagnostic Laboratories
Diagnostic laboratories play a significant role in the cardiac PoC testing market by offering comprehensive diagnostic services. They account for approximately 20% of the market share, providing accurate and timely results that aid in the early detection and management of cardiac conditions. The adoption of PoC testing devices in these laboratories enhances operational efficiency and patient care.

Others
The 'Others' segment includes clinics, home healthcare settings, and emergency medical services that utilize cardiac PoC testing devices for immediate diagnosis and monitoring. This segment, though smaller, is witnessing growth due to the increasing demand for portable and user-friendly diagnostic tools that enable point-of-care testing outside traditional healthcare facilities.

Cardiac Point of Care (PoC) Testing Devices Market, Segmentation by Geography

In this report, the Cardiac Point of Care (PoC) Testing Devices Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Cardiac Point of Care (PoC) Testing Devices Market Share (%), by Geographical Region

North America
North America holds the leading position in the cardiac point-of-care (PoC) testing devices market, contributing nearly 48% of the total share. This dominance stems from the region’s advanced healthcare systems, widespread use of modern diagnostic equipment, and a high prevalence of cardiovascular diseases. The United States plays a central role, with its proactive approach toward early disease detection and patient-centric healthcare strategies.

Europe
Europe stands as a strong regional contributor, accounting for approximately 30% of the market share. The region’s growth is driven by increasing adoption of innovative diagnostic solutions, a growing elderly population, and robust support from public health programs. Nations like Germany, the UK, and France are at the forefront, investing in rapid testing tools to enhance cardiovascular care.

Asia Pacific
Asia Pacific This surge is propelled by a rise in cardiac disease cases, improving access to healthcare services, and substantial public and private investments in medical infrastructure. Key markets such as China, India, and Japan are witnessing a spike in demand for fast, reliable point-of-care testing options.

Middle East and Africa
The Middle East and Africa region represents a smaller but steadily growing portion of the market, with a share of around 7%. Market expansion here is supported by ongoing healthcare reforms, increasing diagnostic awareness, and greater demand for decentralized testing methods. Countries like Saudi Arabia and South Africa are progressively embracing point-of-care technologies in both urban and rural healthcare systems.

Latin America
Latin America accounts for about 5% of the cardiac PoC testing market. Growth in this region is fueled by a rising incidence of heart-related disorders and expanding access to diagnostic tools in public and private healthcare facilities. Brazil and Mexico are among the key contributors, focusing on enhancing early diagnostic capabilities and integrating PoC testing into routine cardiac care.

This report provides an in depth analysis of various factors that impact the dynamics of Cardiac Point of Care (PoC) Testing Devices Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Rising Incidence of Cardiovascular Diseases
• Technological Advancements
• Growing Emphasis on Early Diagnosis

• Increasing Point-of-Care Testing Demand - Increasing point-of-care testing demand is a major driver of growth in the cardiac point of care (PoC) testing devices market. As healthcare providers prioritize rapid diagnosis and early intervention, PoC testing offers a valuable solution by delivering real-time cardiac biomarker results at or near the patient’s location. These devices significantly reduce the time to clinical decision-making, which is especially critical in emergency settings for conditions like acute myocardial infarction or heart failure.

  The growing adoption of decentralized healthcare models and the expansion of ambulatory care, remote clinics, and home-based monitoring have further elevated demand for portable, user-friendly cardiac PoC devices. Their ability to provide immediate diagnostic information enhances workflow efficiency, lowers hospital readmission rates, and improves overall patient outcomes. This rising demand is expected to drive continued innovation and increased market penetration globally.

Restraints

• Strict Regulatory Approval Process
• Expensive Assistive Technology Devices

• Inadequate Reimbursement Framework - An inadequate reimbursement framework significantly hampers the adoption and accessibility of advanced medical treatments across various healthcare systems. In many regions, limited insurance coverage for newer or high-cost procedures prevents patients from opting for optimal care. This particularly affects markets dealing with chronic diseases or precision-based therapies, where continuous or personalized treatment is essential. Without sufficient reimbursement, even well-established therapies see reduced market penetration, as out-of-pocket costs become unaffordable for a large segment of patients.

  The situation is further exacerbated by the lack of uniformity in reimbursement policies across countries and insurance providers. While some public healthcare systems cover the basics, innovative treatments and diagnostics are often excluded due to cost-containment strategies. This discourages healthcare providers from adopting cutting-edge solutions and limits manufacturers’ ability to scale. The absence of clear, streamlined reimbursement approval pathways creates uncertainty and delays for companies entering new markets, especially in regions where pricing and reimbursement decisions are tied to lengthy regulatory reviews.

  From a business perspective, poor reimbursement support discourages R&D investment in highly specialized or rare-disease therapeutics. Developers may deprioritize markets where cost recovery is uncertain, despite clinical demand. This results in a slower introduction of novel treatments and widening disparities in healthcare quality. For patients, this means delayed or denied access to potentially life-saving therapies, especially in low- and middle-income countries. Even in developed markets, gaps in coverage can impact treatment adherence and outcomes.

  To address this issue, stakeholders must focus on collaborative reimbursement strategies that align regulatory approval with payer expectations. Evidence-based evaluations, value-based pricing models, and health technology assessments can improve reimbursement accuracy and justify cost-benefit analyses. Without modernizing reimbursement policies, healthcare systems risk stagnation and diminished returns on innovation. It is crucial that payers, governments, and providers work toward transparent, equitable reimbursement frameworks that prioritize patient outcomes.

Opportunities

• Rising demand for rapid diagnostic solutions
• Strategic Partnerships and Collaborations
• Customization and Personalization

• Integration with Digital Health Solutions - Integration with digital health solutions presents a transformative opportunity for the cardiac point of care (PoC) testing devices market. The convergence of PoC diagnostics with cloud-based platforms, electronic health records (EHRs), and remote monitoring tools enables real-time data sharing, faster decision-making, and improved continuity of care. This digital integration enhances the utility of cardiac PoC devices beyond immediate diagnostics by embedding them into a connected care ecosystem.

  Healthcare providers can now track patient biomarkers longitudinally, analyze trends, and make proactive clinical decisions through AI-driven analytics and telehealth platforms. These capabilities are especially valuable for managing chronic cardiac conditions like heart failure and arrhythmias, where continuous monitoring can significantly reduce the risk of acute episodes. As a result, the demand for digitally integrated PoC solutions is growing rapidly across both hospital and outpatient settings.

  Patients also benefit from this integration through increased engagement and accessibility. Digital health apps and wearable-compatible interfaces allow individuals to access their test results, receive alerts, and stay connected with healthcare teams. This empowerment not only supports adherence to treatment plans but also aligns with trends in personalized and preventive healthcare, further reinforcing the role of PoC diagnostics in modern cardiology.

  As regulatory frameworks evolve to support digital health innovation, the integration of PoC devices with secure, interoperable systems will become a key differentiator for manufacturers. Companies that prioritize seamless digital connectivity, real-time reporting, and user-friendly interfaces will be well-positioned to capitalize on the expanding demand for smart, accessible cardiac diagnostic solutions.

Key players in Cardiac Point of Care (PoC) Testing Devices Market include:

• Abbott Laboratories
• ACON Laboratories Inc
• Alfa Scientific Designs Inc
• American Screening Corporation Inc
• Beckman Coulter Inc
• Bio-Rad Laboratories Inc
• F. Hoffmann-La Roche Ltd
• Nano-Ditech Corporation
• Nova Biomedical Corporation
• Siemens Healthineers AG

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Market Share Analysis
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis